PRINCETON, N.J., Feb. 1 /PRNewswire/ -- Abeille Pharmaceuticals, Inc., a product development company focusing on the development and commercialization of novel dosage forms and unique, proprietary combinations of existing drugs, today announced the initiation of a Phase I pharmacokinetic study of AB-1001, a transdermal patch for chemotherapy induced nausea and vomiting (CINV). AB- 1001 is designed to deliver the drug, a commercially available 5HT3- anatgonist, through the skin for a continuous period of up to five days, thereby providing the patient with sustained relief for CINV.
"We are pleased that our lead product, AB-1001, has been moving forward so rapidly. This Phase I Trial is an open label, three-way, randomized, crossover trial being conducted in normal healthy human volunteers," stated Dr. Kalpana Patel, Vice President, Strategic Planning and Alliance Management. "The objective of the Phase I study is to determine the comparative pharmacokinetics of two doses of AB-1001 with an IV administration of the product in healthy volunteers. The entire study should be completed within three months."
"This is an exciting milestone for Abeille, and it represents an important step in our product development efforts," stated Suresh Borsadia, President and CEO. "We are excited about the prospects of AB-1001 for the prevention of acute and delayed CINV, as this product would fill in important void that exists in CINV therapy today. We intend to maintain the momentum and advance AB-1001 into a dermal toxicity study during the second quarter of this year, with the Phase III studies planned to begin in the fourth quarter of 2006. Abeille has initiated a search for a commercialization partner for AB-1001 and we believe this product will be a good growth generator for companies active in the cancer supportive care area," continued Mr. Borsadia.
About Abeille Pharmaceuticals
Abeille Pharmaceuticals, Inc. is a privately held pharmaceutical company based in Princeton, New Jersey. The Company is focused on the formulation of products by applying advanced delivery technologies to existing drugs. These advanced delivery technologies include oral controlled release and transdermal delivery systems. The new products may benefit patients by requiring a lower dose of medicine, reduced side effects and easier administration of medication, thereby encouraging a patient to use the medication as prescribed. Abeille is dedicated to the development and commercialization of products that address unmet medical needs and improve the quality of life for patients. The Company's initial focus will be on drugs used to treat oncology related discomforts (such as CINV), diabetes and metabolic disorders, and CNS.
For more information, visit our website http://www.abeillepharma.com.
Abeille Pharmaceuticals, Inc.CONTACT: Suresh Borsadia, President and CEO, Abeille Pharmaceuticals,+1-609-951-2204, Fax: +1-609-951-2223, sborsadia@abeillepharma.com
Web site: http://www.abeillepharma.com//
